Related content

Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI

By Erem Cihangir  

Endocrine Journal, Vol. 33, Iss. 3, 2008-06 ,pp. : 270-276

Humana Press, Inc

Access to resources Recommend Favorite

Soluble CD40 Ligand, Plasminogen Activator Inhibitor-1 and Thrombin-Activatable Fibrinolysis Inhibitor-1-Antigen in Normotensive Type 2 Diabetic Subjects without Diabetic Complications

By  

Medical Principles and Practice, Vol. 18, Iss. 4, 2009-06 ,pp. : 266-271

Karger

Access to resources Recommend Favorite

Molecular Advances in Plasminogen Activator Inhibitor 1 Interaction with Thrombin and Tissue-Type Plasminogen Activator

By Stoop A.   van Meijer M.   Horrevoets A.J.G.   Pannekoek H.  

Trends in Cardiovascular Medicine, Vol. 7, Iss. 2, 1997-02 ,pp. : 47-51

Elsevier

Access to resources Recommend Favorite

Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome

By Lindholm Åsa   Bixo Marie   Eliasson Mats   Hudecova Miriam   Arnadottir Ragnheidur   Holte Jan   Poromaa Inger Sundström  

Gynecological Endocrinology, Vol. 26, Iss. 10, 2010-10 ,pp. : 743-748

Informa Healthcare

Access to resources Recommend Favorite

An Inhibitor of Activated Thrombin-Activatable Fibrinolysis Inhibitor Potentiates Tissue-Type Plasminogen Activator-Induced Thrombolysis in a Rabbit Jugular Vein Thrombolysis Model *

By Nagashima M.   Werner M.   Wang M.   Zhao L.   Light D.R.   Pagila R.   Morser J.   Verhallen P.  

Thrombosis Research, Vol. 98, Iss. 4, 2000-05 ,pp. : 333-342

Elsevier

Access to resources Recommend Favorite